IMATINIB RESISTANCE MUTATION ANALYSIS IRMA Test
At DNA Labs UAE, we offer the IMATINIB RESISTANCE MUTATION ANALYSIS (IRMA) test, a molecular diagnostic tool used to detect specific mutations in the BCR-ABL gene. This test is particularly important for patients with chronic myeloid leukemia (CML) who have developed resistance to the drug imatinib.
Imatinib is a tyrosine kinase inhibitor that targets the BCR-ABL fusion protein, which is responsible for the uncontrolled growth of CML cells. However, over time, some CML patients may develop resistance to imatinib due to the emergence of specific mutations in the BCR-ABL gene.
The IRMA test utilizes molecular techniques, such as polymerase chain reaction (PCR) and DNA sequencing, to identify the presence of these specific mutations. To perform the test, a blood or bone marrow sample is obtained from the patient and the DNA is isolated. The DNA is then amplified using PCR and sequenced to identify any mutations in the BCR-ABL gene.
The cost of the IMATINIB RESISTANCE MUTATION ANALYSIS (IRMA) test at DNA Labs UAE is AED 1830.0. The sample condition required is 4 mL (2 mL min.) of whole blood in 1 Lavender Top (EDTA) tube. It is important to ship the sample refrigerated and not freeze it. Along with the sample, please submit the latest BCR-ABL Quantitative report.
The report for the IRMA test will be delivered on Saturday, with the sample required to be submitted by Monday at 11 am. The test is conducted in our Molecular Diagnostics department, under the supervision of an Oncologist.
The results of the IRMA test can help guide treatment decisions for CML patients who have developed resistance to imatinib. If specific resistance mutations are detected, alternative treatment options, such as second-generation or third-generation tyrosine kinase inhibitors, may be considered. On the other hand, if no resistance mutations are found, it suggests that the patient’s resistance to imatinib may be due to other factors, and alternative treatment strategies may be explored.
Overall, the IMATINIB RESISTANCE MUTATION ANALYSIS (IRMA) test offered at DNA Labs UAE is a valuable tool in personalized medicine. It allows for the identification of specific mutations that confer resistance to imatinib, guiding treatment decisions and improving outcomes for CML patients.
| Test Name | IMATINIB RESISTANCE MUTATION ANALYSIS IRMA Test |
|---|---|
| Components | |
| Price | 1830.0 AED |
| Sample Condition | 4 mL (2 mL min.) whole blood in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Submit latest BCR-ABL Quantitative report along with sample. |
| Report Delivery | Sample Mon by 11 am; Report Sat |
| Method | PCR, Sequencing |
| Test type | Pharmacogenomics |
| Doctor | Oncologist |
| Test Department: | MOLECULAR DIAGNOSTICS |
| Pre Test Information | Submit latest BCR-ABL Quantitative report along with sample. |
| Test Details |
The IMATINIB RESISTANCE MUTATION ANALYSIS (IRMA) test is a molecular diagnostic tool used to detect specific mutations in the BCR-ABL gene, which is associated with resistance to the drug imatinib in the treatment of chronic myeloid leukemia (CML). Imatinib is a tyrosine kinase inhibitor that targets the BCR-ABL fusion protein, which is responsible for the uncontrolled growth of CML cells. However, over time, some CML patients may develop resistance to imatinib due to the emergence of specific mutations in the BCR-ABL gene. These mutations alter the structure and activity of the BCR-ABL protein, making it less susceptible to inhibition by imatinib. The IRMA test utilizes molecular techniques, such as polymerase chain reaction (PCR) and DNA sequencing, to identify the presence of specific mutations in the BCR-ABL gene. The test typically involves obtaining a blood or bone marrow sample from the patient and isolating the DNA. The DNA is then amplified using PCR and sequenced to identify any mutations in the BCR-ABL gene. The results of the IRMA test can help guide treatment decisions for CML patients who have developed imatinib resistance. If specific resistance mutations are detected, alternative treatment options, such as second-generation or third-generation tyrosine kinase inhibitors, may be considered. On the other hand, if no resistance mutations are found, it suggests that the patient’s resistance to imatinib may be due to other factors, and alternative treatment strategies may be explored. Overall, the IRMA test is a valuable tool in personalized medicine, allowing for the identification of specific mutations that confer resistance to imatinib and guiding treatment decisions for CML patients. |
